中国实用内科杂志2025，Vol.45Issue(3)：188-193,6.DOI:10.19538/j.nk2025030103
IgA肾病治疗新策略
New treatment strategies for IgA nephropathy
摘要
Abstract
IgA nephropathy(IgAN)is a common glomerular disease worldwide.With current treatments,nearly half of the patients will develop renal failure ten years after the onset of the disease,and there is an urgent need for new therapies.In recent years,with the in-depth research on its pathogenesis,significant progress has been made,especially in key aspects such as the synthesis of pathogenic IgA and complement activation.A number of new drugs have been approved for clinical application.These include the first approved drug for mucosal immunity,a targeted-release formulation(TRF)of budesonide,the regulators targeting the activity of B cells and plasma cells,as well as drugs targeting the complement pathway.All of these drugs have shown the effects of reducing proteinuria in IgAN and delaying the progression of kidney diseases in previous trials.In the future,personalized and multi-target combination therapies are expected to further improve the prognosis of patients.关键词
IgA肾病/靶向治疗/黏膜免疫/补体途径Key words
IgA nephropathy/targeted therapy/mucosal immunity/complement pathway分类
临床医学引用本文复制引用
汤臣,刘立军..IgA肾病治疗新策略[J].中国实用内科杂志,2025,45(3):188-193,6.基金项目
国家自然科学基金(82070731) （82070731）
